Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of Nektar Therapeutics (NKTR, Financials) rose 26.21% to $0.50 as of 11:36 a.m. ET Friday after Jefferies upgraded the stock from Hold to Buy and increas
Key Highlights:
Jefferies upgrades Nektar Therapeutics (NKTR) to "Buy" due to favorable risk-reward dynamics.Anticipation builds for Phase 2b trial results of e
Nektar Therapeutics (NKTR) has submitted a filing for a $300 million mixed securities shelf offering. This development comes as the company receives an upgrade
Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cash and Investments: $269.1 million at the end of 2024.Revenue: $29.2 million for Q4 2024; $98.4 million for the full year 2024.R&D Expenses: $28.7 million fo
Mar 12, 2025 / 09:00PM GMTOperator Good day and thank you for standing by. Welcome to the Nektar Therapeutics fourth quarter 2024 financial results conference c
Nektar (NKTR) delivered earnings and revenue surprises of 215.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Qualit
PR NewswireSAN FRANCISCO, Feb. 26, 2025
SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has com
PR NewswireSAN FRANCISCO and NEW YORK, Feb. 24, 2025
-- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study --SAN FRANCISCO and N
On December 31, 2024, Samlyn Capital, LLC executed a notable transaction by acquiring an additional 467,097 shares of Nektar Therapeutics at a trade price of $0
Eventide Asset Management, LLC, a well-regarded investment firm, recently made a significant adjustment to its holdings in Nektar Therapeutics. On December 31,
On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving Nektar Therapeutics (NKTR), reducing its holdings